Bon Secours is proud to announce a major milestone in the fight against advanced prostate cancer – the successful delivery of our first Pluvicto™ therapy treatment. This powerful new therapy gives renewed hope to patients and families facing the challenges of metastatic prostate cancer.
Pluvicto is part of a new wave of cancer treatments known as molecular radioligand therapy. It’s a highly targeted treatment that uses advanced technology to find and attack cancer cells while leaving most healthy tissue untouched. By targeting a specific marker found on prostate cancer cells, this therapy delivers radiation directly to the disease with incredible precision.
This means fewer side effects and a more personalized, effective treatment experience for patients. Most importantly, it opens the door to better outcomes – helping patients live longer and feel better as they manage their condition.
“This groundbreaking development in the field of molecular radioligand therapy represents a transformative leap forward, instilling hope for our patients and their families grappling with this challenging diagnosis,” said Jennifer DelliSanti, CNMT, Nuclear Medicine Lead for Bon Secours. “Families can find reassurance in knowing that we are now equipped with this sophisticated treatment options that offer a personalized approach to care, catering to the circumstances and needs of each individual.”
This commitment to comprehensive care has earned the Bon Secours St. Francis Cancer Center high patient satisfaction scores, with many patients highlighting the compassionate and personalized approach they have experienced. With approximately $2 million in annual research funding and around 90 active clinical trials, the center is poised to continue its mission of delivering innovative treatments and improving patient outcomes well into the future.
“We are optimistic about the continued development of transformative therapies that will further strengthen our ability to combat this disease. Together, we can provide our patients and their families with renewed hope and a clearer path forward in their journey against metastatic prostate cancer,” said DelliSanti.
Odds are one in nine men will have prostate cancer at some point in their lives.